why choose us

First received: July 27, 2023

Clinical Trial: Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Pre-Exposure Prophylaxis (PrEP)

Study Type: INTERVENTIONAL


Official Title: Linking HIV Prevention and Postpartum Care: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a High-Risk Breastfeeding Population in Botswana

Brief Summary: The goal of this this hybrid safety/implementation study is to evaluate whether using long-acting cabotegravir (CAB-LA) for HIV prevention (PrEP) is acceptable, feasible and safe in post-partum people who are breastfeeding.The main question[s] it aims to answer are:Will CAB-LA injections work well as a way to prevent HIV infection in post-partum people?Will CAB-LA injections be safe in post-partum people and their infants who will be breastfeeding?Participants without HIV who are admitted to the maternity…

Read more